Use of Venetoclax , AML , Sohag , Egypt

Sponsor
Sohag University
Study ID
NCT06993883
Status
Completed

Conditions

  • AML (Acute Myelogenous Leukemia)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    observational study for the result of venetoclax use combined with chemotherapy in AML patients in Sohag governorate

Study Details

retrospective observational study to evaluate the benefit of adding venetoclax to chemotherapy in the first or second line setting in Sohag governorate.

Key Dates

Start date
Mar 1, 2023
Status verified
May 2025
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
43 participants (actual)

Arms

  • Arm: 1st line
    newly diagnosed AML patients unfit for aggressive chemotherapy who received reduced intensity protocols plus venetoclax in the 1st line setting.
  • Arm: 2nd line
    refractory recurrent AML patients after 1st line chemotherapy who received venetoclax plus 2nd line chemotherapy.
  • Arm: 3rd line
    refractory recurrent AML patients after 2 lines chemotherapy who received venetoclax plus 3rd line chemotherapy.

Primary Outcome Measure

response rate [ Time Frame: through the study completion an average 1.5 years ]

Related Studies